GlassScriptPhysician profile
Kye Im Chong
NPI 1376736355
$7,476.01
in general payments reported to CMS, 2019-2025
43 companies · $1,704 in 2025
The $1,704 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $758 · 2020: $156 · 2021: $310 · 2022: $528 · 2023: $2,122 · 2024: $1,897 · 2025: $1,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,674 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,673.57 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $873.79 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $858.13 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $657.92 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $651.40 | 2021-2025 | Airsupra, Breztri, Fasenra |
| Pfizer INC. | $605.02 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $501.34 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $422.79 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $340.52 | 2019-2025 | Otezla, Repatha, Repatha |
| Idorsia Pharmaceuticals US INC | $304.60 | 2023-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $174.02 | 2019 | |
| Exact Sciences Corporation | $159.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $141.25 | 2019-2025 | Spravato |
| Axogen | $127.49 | 2023 | Avance Nerve Graft |
| Smith+Nephew, INC. | $126.50 | 2022 | |
| Medtronic, INC. | $126.07 | 2024-2025 | Symplicity G3, Intellis Adaptivestim |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kye Chong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.